Bio-Plexus and MHA Announce New Purchasing Contract.

Business Editors & Health/Medical Writers

BIOWIRE2K

VERNON, Conn.--(BW HealthWire)--Nov. 28, 2000

Bio-Plexus, Inc. (NASDAQ: BPLX) and Managed Health Care Associates, Inc. (MHA) announced today that they have signed a new purchasing contract for PUNCTUR-GUARD(R)blood collection needles manufactured by Bio-Plexus.

"We are glad to be included in the MHA contracts. MHA recognizes the need to bring innovative products to their customers to help stay at the forefront. We look forward to demonstrating to MHA members why our customers rely on PUNCTUR-GUARD(R) technology to help protect their workers from needlesticks," said John Metz, president and CEO of Bio-Plexus, Inc. "The recent federal and state legislative activity has created increased awareness of the need for the safest blood collection needle," Metz added.

"The increased awareness and recent mandates for needlestick safety have become extremely important to the healthcare industry. This new agreement with Bio-Plexus, Inc. adds a quality partner to our contract portfolio, and it presents further options for our membership to enhance this service in their facilities." said Lawrence S. Irene, CEO of MHA. "Our partnership with Bio-Plexus, Inc. will be an important component in our offering of safety products for MHA members."

MHA, headquartered in Florham Park, NJ, is the dominant GPO to the long-term care industry, covering approximately 70% of the estimated 2.0 million long-term care beds in the U.S. Through acquisitions and internal growth, MHA has expanded to become a leading provider to the acute and non-acute health care, and veterinary markets MHA's reach is a significant factor in its success providing products and services to over 4,714 facilities, including 1,182 long-term care customers servicing an estimated 1.4 million beds and 732 acute care facilities with 135,902 beds.

Bio-Plexus, Inc. (NASDAQ: BPLX), designs, develops, manufactures and holds U.S. and international patents on safety medical needles and other products under the PUNCTUR-GUARD(R), DROP-IT(R), and PUNCTUR-GUARD REVOLUTION(TM) brand names. In studies by the Centers for Disease Control (MMWR, January 1997) and ECRI (Health Devices, June 1998 and October 1999) PUNCTUR-GUARD(R) needles ranked highest in safety of all devices studied. Accidental needlesticks number about one million per year in the United States and can result in the transmission of deadly diseases including HIV and Hepatitis B and C.

NOTE: THIS PRESS RELEASE MAY CONTAIN FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. FORWARD-LOOKING STATEMENTS MAY BE IDENTIFIED BY THE USE OF SUCH TERMINOLOGY AS "BELIEVES," "EXPECTS," "MAY," "WILL," "SHOULD," "ANTICIPATES," "PLANS," "ESTIMATES," AND "INTENDS" OR DERIVATIONS OR NEGATIVES THEREOF OR COMPARABLE TERMINOLOGY, OR DISCUSSIONS OF STRATEGY THAT INVOLVES RISKS (KNOWN AND UNKNOWN) AND UNCERTAINTIES. THE COMPANY'S ACTUAL RESULTS MAY DIFFER MATERIALLY FROM THOSE PROJECTED IN THE FORWARD-LOOKING STATEMENTS AS A RESULT OF, AMONG OTHER FACTORS, GENERAL ECONOMIC CONDITIONS AND GROWTH IN THE SAFETY MEDICAL PRODUCTS INDUSTRY, COMPETITIVE FACTORS AND PRICING PRESSURES, CHANGES IN PRODUCT MIX, PRODUCT DEMAND, RISK OF DEPENDENCE ON THIRD PARTY SUPPLIERS AND FINANCIERS, ABILITY TO OBTAIN FINANCING, AS WELL AS OTHER FACTORS DESCRIBED FROM TIME TO TIME IN THE COMPANY'S PERIODIC REPORTS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION OR DISCUSSED IN OTHER PRESS RELEASES ISSUED BY THE COMPANY. THE COMPANY UNDERTAKES NO OBLIGATION TO UPDATE OR ADVISE UPON ANY SUCH FORWARD-LOOKING STATEMENT.